Is Pertuzumab included in medical insurance?

Pertuzumab (Pertuzumab) has been approved by the relevant policies of the National Medical Insurance Bureau and is covered by Class B medical insurance after being launched in China. However, it can be paid by medical insurance only in the following situations, and the payment will not exceed 12 months, including neoadjuvant therapy for patients with HER2-positive locally advanced, inflammatory or early breast cancer and adjuvant therapy for patients with high recurrence risk HER2-positive early breast cancer.

Pertuzumab is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2. It is usually used in combination with other drugs, such as trastuzumab. Pertuzumab and trastuzumab bind to different sites on the HER2 receptor. The two drugs have complementary anti-tumor activities. Pertuzumab not only extends the progression-free survival (PFS) of patients with metastatic breast cancer, but also improves the prognosis of patients with early-stage breast cancer. However, the therapeutic benefit of pertuzumab is relatively small in patients with nonvisceral metastases or small primary tumors that are node-negative. In addition, side effects of cardiac dysfunction and diarrhea must be noted.

Pertuzumab is a strictly controlled drug, and its purchase channels are restricted. The price of each box of the domestic original drug may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.